Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacogenomic Testing in the Clinical Laboratory: Historical Progress and Future Opportunities

  • Ann M. Moyer (Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic) ;
  • John L. Black (Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic)
  • Received : 2024.12.09
  • Accepted : 2025.03.04
  • Published : 2025.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Pharmacogenomics is a rapidly evolving field with a strong foundation in basic science dating back to 1960. Pharmacogenomic findings have been translated into clinical care through collaborative efforts of clinical practitioners, pharmacists, clinical laboratories, and research groups. The methods used have transitioned from targeted genotyping of relatively few variants in individual genes to multiplexed multi-gene panels, and sequencing-based methods are likely on the horizon; however, no system exists for classifying and reporting rare variants identified via sequencing-based approaches. Laboratory testing in pharmacogenomics is complex for several genes, including cytochrome P450 2D6 (CYP2D6), HLA-A, and HLA-B, owing to a high degree of polymorphisms, homology with other genes, and copy-number variation. These loci require specialized methods and familiarity with each gene, which may persist during the transition to next-generation sequencing. Increasing implementation across laboratories and clinical facilities has required cooperative efforts to develop standard testing targets, nomenclature, and reporting practices and guidelines for applying the results clinically. Beyond standardization, harmonization between pharmacogenomics and the broader field of genomic medicine may be essential for facilitating further adoption and realizing the full potential of personalized medicine. In this review, we describe the evolution of clinical laboratory testing for pharmacogenomics, including standardization efforts and the anticipated transition from targeted genotyping to sequencing-based pharmacogenomics. We speculate on potential upcoming developments, including pharmacoepigenetics, improved understanding of the impact of non-coding variants, use of large-scale functional genomics to characterize rare variants, and a renewed interest in polygenic risk or combinatorial approaches, which will drive the progression of the field.

Keywords

References

  1. Vogel F. Moderne Probleme der Humangenetik. In: Ergeb Inn Med Kinderheilkd. Heilmeyer L, Schoen R, et al., eds. Berlin, Heidelberg: Springer 1959:52–125.
  2. Evans DA and Clarke CA. Pharmacogenetics. Br Med Bull 1961;17:234–40. https://doi.org/10.1093/oxfordjournals.bmb.a069915
  3. Snow JL and Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995;32:114–6. https://doi.org/10.1016/0190-9622(95)90195-7
  4. Spielberg SP. Pharmacogenetics and blood dyscrasias. Eur J Haematol Suppl 1996;60:93–7. https://doi.org/10.1111/j.1600-0609.1996.tb01653.x
  5. Hodgson J and Marshall A. Pharmacogenomics: will the regulators approve? Nat Biotechnol 1998;16:243–6. https://doi.org/10.1038/nbt0398-243
  6. Lennard L and Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18:328–34. https://doi.org/10.1097/00007691-199608000-00003
  7. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19–52. https://doi.org/10.1146/annurev.pharmtox.39.1.19
  8. Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, et al. Very important pharmacogene summary: thiopurine Smethyltransferase. Pharmacogenet Genomics 2010;20:401–5. https://doi.org/10.1097/FPC.0b013e3283352860
  9. Moyer AM, Rohrer Vitek CR, Giri J, Caraballo PJ. Challenges in ordering and interpreting pharmacogenomic tests in clinical practice. Am J Med 2017;130:1342–4. https://doi.org/10.1016/j.amjmed.2017.07.012
  10. Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther 2016;99:172–85. https://doi.org/10.1002/cpt.280
  11. Andrawiss M. First phase of HapMap project already helping drug discovery. Nat Rev Drug Discov 2005;4:947. https://doi.org/10.1038/nrd1918
  12. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques 2002;32: S48–54. https://doi.org/10.2144/jun0209
  13. Bender K. SNaPshot for pharmacogenetics by minisequencing. Methods Mol Biol 2005;297:243–52.
  14. Griese EU, Läpple F, Eichelbaum M. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction. Pharmacogenetics 1999;9:389–91. https://doi.org/10.1097/00008571-199906000-00014
  15. Pickering JW, McMillin GA, Gedge F, Hill HR, Lyon E. Flow cytometric assay for genotyping cytochrome P450 2C9 and 2C19: comparison with a microelectronic DNA array. Am J Pharmacogenomics 2004;4:199–207. https://doi.org/10.2165/00129785-200404030-00007
  16. Shi MM, Bleavins MR, de la Iglesia FA. Technologies for detecting genetic polymorphisms in pharmacogenomics. Mol Diagn 1999;4:343–51. https://doi.org/10.1016/S1084-8592(99)80011-3
  17. Koch WH. Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov 2004;3:749–61. https://doi.org/10.1038/nrd1496
  18. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006;10: 135–51. https://doi.org/10.1007/BF03256453
  19. Hajra A, Sorenson RC, La Du BN. Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes. Pharmacogenetics 1992;2:78–88. https://doi.org/10.1097/00008571-199204000-00005
  20. Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; 16:353–7. https://doi.org/10.1097/01.fpc.0000197468.16126.cd
  21. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943–50.
  22. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, IngelmanSundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825–9. https://doi.org/10.1073/pnas.90.24.11825
  23. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553–6. https://doi.org/10.1007/BF00279968
  24. Panserat S, Mura C, Gérard N, Vincent-Viry M, Galteau MM, Jacoz-Aigrain E, et al. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 1995;40:361–7. https://doi.org/10.1111/j.1365-2125.1995.tb04558.x
  25. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351–5. https://doi.org/10.1097/00008571-199608000-00008
  26. Black JL 3rd, Walker DL, O'Kane DJ, Harmandayan M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos 2012;40:111–9. https://doi.org/10.1124/dmd.111.040832
  27. Kramer WE, Walker DL, O'Kane DJ, Mrazek DA, Fisher PK, Dukek BA, et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics 2009;19:813–22. https://doi.org/10.1097/FPC.0b013e3283317b95
  28. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215–23. https://doi.org/10.1097/00008571-199508000-00005
  29. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using nextgeneration DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn 2016;18:438–45. https://doi.org/10.1016/j.jmoldx.2016.01.003
  30. Matey ET, Ragan AK, Oyen LJ, Vitek CR, Aoudia SL, Ragab AK, et al. Nine-gene pharmacogenomics profile service: the Mayo Clinic experience. Pharmacogenomics J 2022;22:69–74. https://doi.org/10.1038/s41397-021-00258-0
  31. Moyer AM and Gandhi MJ. Human leukocyte antigen (HLA) testing in pharmacogenomics. Methods Mol Biol 2022;2547:21–45. https://doi.org/10.1007/978-1-0716-2573-6_2
  32. Malekkou A, Tomazou M, Mavrikiou G, Dionysiou M, Georgiou T, Papaevripidou I, et al. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report. BMC Med Genomics 2024;17:78. https://doi.org/10.1186/s12920-024-01846-2
  33. Saarenheimo J, Wahid N, Eigeliene N, Ravi R, Salomons GS, Ojeda MF, et al. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. Cancer Chemother Pharmacol 2021;87:657–63. https://doi.org/10.1007/s00280-021-04236-y
  34. Marathe DD, Jauslin PM, Kleijn HJ, de Miranda Silva C, Chain A, Bateman T, et al. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics Syst Pharmacol 2023;12:1499–510. https://doi.org/10.1002/psp4.13028
  35. Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, et al. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med 2018;20:622–9. https://doi.org/10.1038/gim.2017.156
  36. Wigle TJ, Medwid S, Ross C, Schwarz UI, Kim RB. DPYD Exon 4 deletion associated with fluoropyrimidine toxicity and importance of copy number variation. Curr Oncol 2023;30:663–72. https://doi.org/10.3390/curroncol30010051
  37. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2021;110: 563–72. https://doi.org/10.1002/cpt.2350
  38. Moyer AM, McMillin GA, Long TA, Gandhi MJ, Mao R, Smock KJ, et al. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. Arch Pathol Lab Med 2020;144:1057–66. https://doi.org/10.5858/arpa.2019-0478-CP
  39. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989;8:1–13. https://doi.org/10.1089/dna.1.1989.8.1
  40. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193–201. https://doi.org/10.1097/00008571-199606000-00001
  41. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 2000;10:91–3. https://doi.org/10.1097/00008571-200002000-00012
  42. Oscarson M and Ingelman-Sundberg M. CYPalleles: a web page for nomenclature of human cytochrome P450 alleles. Drug Metab Pharmacokinet 2002;17:491–5. https://doi.org/10.2133/dmpk.17.491
  43. Gaedigk A, Casey ST, Whirl-Carrillo M, Miller NA, Klein TE. Pharmacogene Variation Consortium: a global resource and repository for pharmacogene variation. Clin Pharmacol Ther 2021;110:542–5. https://doi.org/10.1002/cpt.2321
  44. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, et al. The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther 2018;103:399–401. https://doi.org/10.1002/cpt.910
  45. Gaedigk A, Whirl-Carrillo M, Pratt VM, Miller NA, Klein TE. PharmVar and the landscape of pharmacogenetic resources. Clin Pharmacol Ther 2020;107:43–6. https://doi.org/10.1002/cpt.1654
  46. Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 2013;23:242–8. https://doi.org/10.1097/FPC.0b013e32835f1cc0
  47. Barker DJ, Maccari G, Georgiou X, Cooper MA, Flicek P, Robinson J, et al. The IPD-IMGT/HLA Database. Nucleic Acids Res 2023;51:D1053–60. https://doi.org/10.1093/nar/gkac1011
  48. Robinson J, Barker DJ, Marsh SGE. 25years of the IPD-IMGT/HLA Database. HLA 2024;103:e15549. https://doi.org/10.1111/tan.15549
  49. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SG. IMGT/HLA database – a sequence database for the human major histocompatibility complex. Tissue Antigens 2000;55:280–7. https://doi.org/10.1034/j.1399-0039.2000.550314.x
  50. Relling MV and Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;89:464–7. https://doi.org/10.1038/clpt.2010.279
  51. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 2017;19:215–23. https://doi.org/10.1038/gim.2016.87
  52. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci 2020;13:116–24. https://doi.org/10.1111/cts.12692
  53. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, et al. Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn 2021;23:1047–64. https://doi.org/10.1016/j.jmoldx.2021.05.013
  54. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, et al. Recommendations for clinical warfarin genotyping allele selection: a report of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn 2020;22:847–59. https://doi.org/10.1016/j.jmoldx.2020.04.204
  55. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM, et al. Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn 2019;21:746–55. https://doi.org/10.1016/j.jmoldx.2019.04.003
  56. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn 2022;24:1051–63. https://doi.org/10.1016/j.jmoldx.2022.06.007
  57. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn 2023;25:619–29. https://doi.org/10.1016/j.jmoldx.2023.06.008
  58. Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the Association for Molecular Pathology. J Mol Diagn 2018;20:269–76. https://doi.org/10.1016/j.jmoldx.2018.01.011
  59. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn 2024;26:851–63. https://doi.org/10.1016/j.jmoldx.2024.05.015
  60. Neu M, Yang Y, Scott SA. Long-read sequencing for germline pharmacogenomic testing. Adv Mol Pathol 2023;6:99–109. https://doi.org/10.1016/j.yamp.2023.08.004
  61. Ly RC, Tayeh MK, Ji Y. Education of future pharmacogenomics laboratory directors. Adv Mol Pathol 2024;7:33–41. https://doi.org/10.1016/j.yamp.2024.06.003
  62. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24. https://doi.org/10.1038/gim.2015.30
  63. Lopes JL, Harris K, Karow MB, Peterson SE, Kluge ML, Kotzer KE, et al. Targeted genotyping in clinical pharmacogenomics: what is missing? J Mol Diagn 2022;24:253–61. https://doi.org/10.1016/j.jmoldx.2021.11.008
  64. Wang L, Scherer SE, Bielinski SJ, Muzny DM, Jones LA, Black JL 3rd, et al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: the Mayo-Baylor Right 10K study. Genet Med 2022;24:1062–72. https://doi.org/10.1016/j.gim.2022.01.022
  65. Gong L, Whirl-Carrillo M, Scott S, Caudle K, Moyer A, Klein C, et al. P179: the ClinGen Pharmacogenomics Working Group: developing frameworks for evaluating pharmacogenomic gene validity and actionability. Genet Med Open 2024;2:101076. https://doi.org/10.1016/j.gimo.2024.101076
  66. Oh RY, AlMail A, Cheerie D, Guirguis G, Hou H, Yuki KE, et al. A systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods. HGG Adv 2024;5: 100299.
  67. AlSaeed MJ, Ramdhan P, Malave JG, Eljilany I, Langaee T, McDonough CW, et al. Assessing the performance of in silico tools and molecular dynamics simulations for predicting pharmacogenetic variant impact. Clin Pharmacol Ther 2024;116:1082–9. https://doi.org/10.1002/cpt.3348
  68. Claussnitzer M, Parikh VN, Wagner AH, Arbesfeld JA, Bult CJ, Firth HV, et al. Minimum information and guidelines for reporting a multiplexed assay of variant effect. Genome Biol 2024;25:100. https://doi.org/10.1186/s13059-024-03223-9
  69. Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, et al. Pharmacogenomic next-generation DNA sequencing: lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19. Drug Metab Dispos 2019;47: 425–35. https://doi.org/10.1124/dmd.118.084269
  70. Suiter CC, Moriyama T, Matreyek KA, Yang W, Scaletti ER, Nishii R, et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci U S A 2020;117: 5394–401. https://doi.org/10.1073/pnas.1915680117
  71. Gasperini M, Starita L, Shendure J. The power of multiplexed functional analysis of genetic variants. Nat Protoc 2016;11:1782–7. https://doi.org/10.1038/nprot.2016.135
  72. Cagiada M, Johansson KE, Valanciute A, Nielsen SV, Hartmann-Petersen R, Yang JJ, et al. Understanding the origins of loss of protein function by analyzing the effects of thousands of variants on activity and abundance. Mol Biol Evol 2021;38:3235–46. https://doi.org/10.1093/molbev/msab095
  73. Cheng J, Novati G, Pan J, Bycroft C, Žemgulytė A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 2023;381:eadg7492. https://doi.org/10.1126/science.adg7492
  74. Ellingford JM, Ahn JW, Bagnall RD, Baralle D, Barton S, Campbell C, et al. Recommendations for clinical interpretation of variants found in noncoding regions of the genome. Genome Med 2022;14:73. https://doi.org/10.1186/s13073-022-01073-3
  75. Smith DA, Sadler MC, Altman RB. Promises and challenges in pharmacoepigenetics. Camb Prism Precis Med 2023;1:e18. https://doi.org/10.1017/pcm.2023.6
  76. Mukerjee G, Huston A, Kabakchiev B, Piquette-Miller M, van Schaik R, Dorfman R. User considerations in assessing pharmacogenomic tests and their clinical support tools. NPJ Genom Med 2018;3:26. https://doi.org/10.1038/s41525-018-0065-4
  77. Bousman CA and Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogeneticbased decision support tools. Pharmacogenomics J 2018;18:613–22. https://doi.org/10.1038/s41397-018-0027-3
  78. Zhai S, Mehrotra DV, Shen J. Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities. Brief Bioinform 2023;25:bbad470. https://doi.org/10.1093/bib/bbad470
  79. Zhai S, Zhang H, Mehrotra DV, Shen J. Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods. Nat Commun 2022;13:5278. https://doi.org/10.1038/s41467-022-32407-9
  80. Simona A, Song W, Bates DW, Samer CF. Polygenic risk scores in pharmacogenomics: opportunities and challenges-a mini review. Front Genet 2023;14:1217049. https://doi.org/10.3389/fgene.2023.1217049
  81. Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Dev Ther 2019;13: 2405–12. https://doi.org/10.2147/DDDT.S153719
  82. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloidrelated imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 2023;146:4414–24. https://doi.org/10.1093/brain/awad188
  83. Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloidrelated imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. JAMA Neurol 2022;79:291–304. https://doi.org/10.1001/jamaneurol.2021.5205
  84. Shirley M. Casimersen: First approval. Drugs 2021;81:875–9. https://doi.org/10.1007/s40265-021-01512-2